Browse studies

Find your next paid study

67 recruiting studies matching your filters

A Phase I/Ib Study of Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV …

Lung Cancer MetastaticEGFR Gene Mutation

Estimated

~$10 – $7,500

Collin BlakelyNCT04085315

The Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Program (SDS-GPS Program)

The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in t…

Shwachman-Diamond SyndromeSDSIBMF+24 more

Estimated

~$10 – $1,050

Shwachman-Diamond Syndrome Alliance IncNCT06999954

Natural History Study for the ASXL-Related Disorders and Chromatinopathies

A registry focused on the natural history, management and treatment of patients with Bohring-Opitz Syndrome (ASXL1), Shashi-Pena Syndrome (ASXL2) and Bainbridg…

Bohring-Opitz SyndromeASXL1 Gene MutationShashi-Pena Syndrome+3 more

Estimated

~$10 – $750

University of California, Los AngelesNCT03303716

Phase 2

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for c…

Hematologic MalignancyAcute LeukemiaRemission+21 more

Estimated

~$10 – $6,250

Masonic Cancer Center, University of Minnesota

Phase 3

The Cancer of the Pancreas Screening-5 CAPS5)Study

Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be re…

Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT02000089

Observational

A Prospective, Randomized Trial to Compare Telegenetics to Counseling Via a Novel Genetic Information Assistant in High-risk Cancer Patients.

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for…

Gene Mutation-Related CancerGenetic Predisposition

Estimated

~$10 – $6,250

University of VirginiaNCT06089421

Phase 2

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradia…

Salivary Gland CancerHER2 Gene Mutation

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT04620187

Phase 2

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPN…

Wilms TumorRhabdoid TumorMalignant Peripheral Nerve Sheath Tumors+4 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05985161

Phase 1

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC+2 more

Estimated

~$10 – $8,750

Jacobio Pharmaceuticals Co., Ltd.NCT05490472

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer …

Uveal MelanomaCutaneous MelanomaBAP1 Gene Mutation+5 more

Estimated

~$10 – $1,125

Mohamed Abdel-RahmanNCT04792463

Phase 1

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated/Deleted AML Patients

Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients

Acute Myeloid LeukemiaTP53 Gene Mutation

Estimated

~$10 – $6,250

Northside Hospital, Inc.NCT07511062

Drug Discovery for Parkinson's With Mutations in the GBA Gene

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by usi…

Parkinson DiseaseGaucher DiseaseHealthy+1 more

Estimated

~$10 – $750

New York Stem Cell Foundation Research InstituteNCT05536388